Home/Pipeline/GDC-0587 (RGT-587)

GDC-0587 (RGT-587)

HR+/HER2- Breast Cancer

Phase 1Licensed to Genentech

Key Facts

Indication

HR+/HER2- Breast Cancer

Phase

Phase 1

Status

Licensed to Genentech

Company

Regor Therapeutics

About Regor Therapeutics

Regor Therapeutics uses AI-powered discovery to create small molecule drugs for oncology and metabolic diseases, then partners with pharma giants for development.

View full company profile

Therapeutic Areas

Oncology Metabolism Immunology

Other HR+/HER2- Breast Cancer Drugs

Drug	Company	Phase	Status
GDC-4198 (RGT-419B)	Regor Therapeutics	Phase 1	Licensed to Genentech
Kisqali® (ribociclib)	Novartis	Approved / Lifecycle	Active
HS-10353	Hansoh Pharma	Phase I	Active